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which in turn could support the justiﬁcation of HSCT
pharmacy services.545
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Background: Sulfamethoxazole/trimethoprim (SMX/TMP) is
the current gold standard for PCP prophylaxis in hemato-
poietic stem cell transplant (HSCT) patients. There are
several second line options for prophylaxis but many,
including intravenous (IV) pentamidine, have not been
proven to be as effective or as safe as SMX/TMP in the pe-
diatric HSCT population. There is increasing use of IV pen-
tamidine in the pediatric HSCT population, as it is easily
given once monthly, with no issues regarding compliance or
vomiting. However, there are limited published data to
support safety and efﬁcacy of this approach. This study was
aimed to determine the safety and efﬁcacy of IV pentamidine
in preventing PCP infection in our pediatric HSCT patients.
Methods: A retrospective chart review was conducted with
IRB approval to evaluate all HSCT patients at Cincinnati
Children’s Hospital Medical Center (CCHMC) that received at
least one dose of IV pentamidine from January 2010 to July
2013. The primary outcome, pentamidine efﬁcacy, was
evaluated through lack of breakthrough PCP infection. The
secondary outcome, pentamidine safety, was evaluated by
adverse events leading to pentamidine discontinuation.
Results: Total of 285 HSCT patients received at least one dose
of IV pentamidine and were included in the ﬁnal analyses.
Median age of patients was 5 years (range: 0.2 to 32 years).
Patients were on pentamidine prophylaxis for a median of 5
months (range 1-44 months). Only 1 patient developed
breakthrough PCP infection while receiving IV pentamidine
prophylaxis (0.35%). Two patients were diagnosed with
toxoplasmosis while receiving pentamidine prophylaxis
(0.7%). Twenty patients (7%) experienced an adverse event
leading to discontinuation of pentamidine, with tachycardia
being the most common adverse event leading to discon-
tinuation of pentamidine. The rate of adverse effects seen
with pentamidine is comparable to that seen in patients
receiving SMX/TMP prophylaxis which is associated with
adverse effects ranging from 3.1-59%.
Conclusion: In a three year time span only 1 patient
(0.35%) receiving IV pentamidine prophylaxis had a
breakthrough PCP infection. Although SMX/TMP is
considered ﬁrst line for PCP prophylaxis, based on the
results of this study, IV pentamidine should be considered
a safe and effective alternative in pediatric HSCT patients.
Of note, pentamidine does not provide toxoplasmosis
suppression, a consideration for children considered at
high risk of reactivation.547
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Background: Stem cell transplant patients who are hepatitis
B negative at the time of transplant and receive stem cells
from a hepatitis positive donor have a higher risk of liver
related post-transplant complications and hepatitis viral
positivity. The use of lamivudine has been documented in the
literature as chemoprophylaxis for preventing viral reac-
tivation in positive patients and also surface antigen negative
patients receiving stem cell product from hepatitis positive
donors. The expected duration of chemoprophylaxis with
lamivudine therapy is multiple months following stem cell
transplant. This is a case series of using a two dose course of
hepatitis B immune globulin, without lamivudine, for the
prevention of viral seroconversion in stem cell transplant
recipients.
Methods: This is a single center retrospective chart review of
three pediatric stem cell transplant patients who were pre-
scribed hepatitis B immune globulin for prophylaxis of
seroconversion of hepatitis B. Hepatitis B immune globulin
0.06mL per kilogram was administered as two doses, on day
-1 or day 0, and repeated four weeks later. All patients
received allogeneic transplantation from matched related
donors, found to be positive for hepatitis B prior to stem cell
harvest. Diagnoses for stem cell transplant of the patients
were acute lymphoblastic leukemia, congenital myeloﬁbrosis
and cartilage hair hypoplasia. Patient age ranged from 1 to 17
years.
Results: At median of 20 months follow up (range 12-32
months), no patients were reported to have a positive hep-
atitis B DNA after stem cell transplant. No cases of veno-
occlusive disease of the liver were observed. This small case
series may present an alternative, simpler prophylaxis
regimen that is effective at preventing hepatitis viral trans-
mission during stem cell transplant.548
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Background: High-dose chemotherapy with autologous
hematopoietic stem cell transplantation (auto-HCT) can be
an effective treatment for systemic light chain amyloidosis
(AL). However, signiﬁcant morbidity may occur in AL pa-
tients undergoing peripheral blood stem cell (PBSC) mobili-
zation, especially if they have cardiac or renal involvement.
Reported complications include ﬂuid overload, cardiac ar-
rhythmias, bleeding events, and infections.
Methods: We identiﬁed 101 patients with AL who under-
went PBSC mobilization and collection with ﬁlgrastim at a
dose of 10 mcg/kg/day between 2006 and 2013. Fifteen pa-
tients (15%) also received plerixafor at a dose of 0.16-0.24mg/
kg/day after at least 4 days of ﬁlgrastim. The primary
